Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Raptiva efalizumab: Phase III; Under review to treat psoriasis

In a 12-week, open-label extension of a double-blind, placebo-controlled U.S. Phase III study, 161 of

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE